A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer
ConditionProstate Cancer
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexMale
Age18+
SponsorMatrix Biomed, Inc.
About this trial
A single patient compassionate use clinical trial for the use of MBM-02 (TEMPOL) for the treatment of prostate cancer. The single patient will be exposed to orally administered TEMPOL for up to 12 months at a maximum total daily dose of 800mg.
Eligibility criteria
Qualifiers
Biochemical Recurrent Prostate Cancer
Disqualifiers
None
Trial design
Treatments tested in this trial
- MBM-02 (Tempol)
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov